Kaufman et al. HCA Healthcare Journal of Medicine (2020) 1:2
https://doi.org/10.36518/2689-0216.1060

News
The Coronaviruses: Past, Present, Future
Kimball Kaufman DO,1 Shobhit Keswani MD,1 Cristobal Cintron, MSc, DrPhc,2
Hossein Akhondi, MD1

Abstract

Author affiliations are listed
at the end of this article.
Correspondence to:
Kimball Kaufman DO

Description

The current coronavirus pandemic is unparalleled in recent memory and fundamentally
unique. It has been more than a century since humanity fought the Spanish flu pandemic.
That widespread disease devastated a World War I-ravaged population when there was
a relative paucity of medical knowledge. Coronavirus, on the other hand, is now befalling
upon a developed world with advanced infrastructure and health systems; wherein access
to medical information and technology is abundant. Yet, it has proven to be a destroyer of
economies and populations without geographical partiality.
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This article is meant to be a broad analysis of the virus, which is causing global disruption
from both a historical and clinical perspective. We are receiving new facts and figures daily.
Thus, this review is up-to-date as much as it can be and meant to serve as a general knowledge base for all involved in the fight.
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Introduction

The coronaviruses are enveloped ribonucleic
acid (RNA) viruses that are common among human and animal populations. Six known species
affect humans, four of which cause common
cold symptoms (strains 229E, OC43, NL63, and
HKU1). The two other strains — severe acute
respiratory syndrome coronavirus (SARS-CoV)
and Middle East respiratory syndrome coronavirus (MERS-CoV) — are zoonotic in origin
and can be fatal in humans. SARS-CoV was
the causal agent of the severe acute respiratory syndrome outbreaks in 2002 and 2003 in
Guangdong Province, China. MERS-CoV was
the pathogen responsible for severe respiratory
disease outbreaks in 2012 in the Middle East.
SARS-CoV-2 (COVID-19) is the seventh known
coronavirus to infect people.
All three examples are positive‐strand RNA
viruses, and the virion consists of a nucleocapsid core encapsulated by the three envelope

glycoproteins: spike (S), membrane (M) and
envelope (E). The RNA is packaged by the nucleocapsid (N) protein into a helical nucleocapsid. (Figure 1) The N protein is thought to be a
potential source of its pathogenicity, whereas
the S protein is a target of the cellular immune
response.1
In this article, we will briefly compare the three
outbreaks in terms of historical background,
epidemiology, virology, clinical picture and lasting impact. Regarding COVID-19, we have synthesized data from the most significant known
studies to provide a summary of clinical signs
and symptoms, imaging findings, case fatality,
current treatment options and lastly, specific
steps that healthcare providers can take to
prevent, manage and prepare for the future of
this evolving pandemic.

Key Epidemiologic Terms

A common outbreak refers to an exposure of
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Figure 1. SARS-CoV Nucleocapsid and Glycoproteins
Credit: Assay Genie. Published with permission.
a susceptible population to a common source
of a pathogen at the same time, such as at a
restaurant or picnic. The term endemic reflects
the occurrence of a disease at a relatively constant level in a given setting.
An epidemic is the occurrence of cases of illness, specific health-related behavior or other
health-related events clearly above average expectancy in a community or region. The number
of cases indicating the presence of an epidemic
varies according to the agent, size and type of
the population exposed, previous experiences,
lack of exposure to the disease, and time and
place of occurrence. Epidemicity is thus a relative term. Two cases of a disease long absent

from a population or the first invasion by a
disease not previously recognized, associated in
time and place, may be sufficient to be considered an epidemic.2
A pandemic refers to an epidemic occurring
over an extensive area and usually affecting a
large portion of the population.3 Key pandemics
from the past include the 1918 Spanish flu (50100 million deaths), 1957 Asian flu (1.1 million
deaths), 1968 Hong Kong flu (1 million deaths),
1980s AIDS pandemic (25 million fatalities)
and the 2009 Swine flu (100,000 to 400,000
deaths). The WHO pronounced COVID-19 a
pandemic on March 12, 2020. (Table 1)

Table 1. Comparison of Coronaviruses
Disease

Flu

SARS

MERS

COVID-19

Pathogen

Influenza virus

SARS-CoV

MERS-CoV

SARS-CoV-2

Country of origin

Worldwide

China

Saudi Arabia

Wuhan, China

First outbreak

1918

2003

2012

2019

Type of the virus

RNA

RNA

RNA

RNA

Pathogen origin (zoonotic)

Avian, Swine, etc.

Bats, Civet

Bats, Camel

Bats

Incubation in days

1-4

2-7

6

4-14

Community attack rate

10-20%

10-60%

4-13%

30-40%

Hospitalization rate

2%

Most cases

Most cases

~19%

Fatality rate

0.05-0.01%

9.6-11%

34.40%

~3.40%

Total deaths (WHO)

12,000-61,000
annually

916

858

Ongoing

Created using BioRender.com Credit: Keswani S. Department of Internal Medicine, MountainView Hospital.
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SARS Epidemic, 2003

The SARS virus originated in the province of
Guangdong in southern China in November
2002, where it initially was thought to have
arisen from bat-to-civet transmission.4 Civets are a food source in China, and although
they have long been suspected of playing a
role in SARS transmission, SARS experts have
stopped short of saying the animals are the
natural reservoir of the virus or its conveyor to
humans. This strain was discovered by Italian
physician Dr. Carlo Urbani in February 2003.
Later that year, he would succumb to the
disease. The CDC has noted that viruses very
similar to SARS-CoV have been found in civets
and that some civet handlers had evidence
of infection with SARS-CoV or a very similar
illness.
During the outbreak, which lasted just six
months, more than 8000 patients were infected, and 900 died throughout 29 countries. This
resulted in a mortality rate of approximately
9%. More than half of the cases and roughly
one-third of the deaths occurred in mainland
China. There were only eight laboratory-confirmed cases in the US. No cases of SARS have

been reported anywhere in the world since
2004.5, 6 (Figure 2)
Like COVID-19, the mortality rate was higher
in the elderly, approaching 50% for this subset
of patients. Notably, more than one-third of
the initial cases occurred in food handlers and
health care workers. The SARS outbreak was an
epidemic based on population reports.

MERS Outbreak, 2012

Middle East respiratory syndrome-coronavirus
(MERS-CoV) is also a zoonotic coronavirus that
has infected humans time and again via direct
or indirect contact with dromedary camels in
the Arabian Peninsula. The evidence available to
date suggests that the virus was spread from
bats to camels sometime in the mid-1990s in
South Korea. The virus then appeared to have
spread from camels to humans in the early
2010s.7 The original bat host species is unknown, and MERS-CoV has a different genetic
makeup from SARS and COVID-19. It is an
enveloped, positive-sense, ss-RNA virus that
enters cells by binding to the Dipeptidyl peptidase-4 (DPP4) receptor, which is also known
as CD-26. In humans, the virus has a predilec-

Figure 2. SARS Epidemic
Source: WHO
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Figure 3. SARS-COVID Solar Corona Appearance
Credit: Helmholtz-Zentrum Berlin
tion for non-ciliated bronchial epithelial cells.
These makeup approximately 20% of respiratory epithelial cells, so large numbers of virions
are required to cause a severe infection. This
mechanism is unusual in that most respiratory viruses target ciliated cells. The amino acid
sequence of DPP4 is found in both bronchial
epithelium and the kidneys, which explains why
the virus affects the lung and causes kidney
insufficiency. The virus also appears to have the
ability to elude innate immune responses and
subdue interferon production.
Between 2012 and 2017, over 2000 laboratory-confirmed cases of MERS-CoV infection
were reported. Over 80% of the infections
occurred in Saudi Arabia. The largest focus outside of the Middle East occurred in Korea with
nearly 200 cases. Only two patients in the US
ever tested positive for MERS.7 The mortality
rate was initially reported at near an astonishing 100% and then decreased to 35%.
No sustained human-to-human transmission
has occurred anywhere in the world. However, limited, non–sustained, human-to-human
transmission in health-care facilities was a
prominent feature of this virus. The WHO never classified this as a health emergency.6
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SARS-CoV-2 (COVID-19)
Pandemic, 2019-2020

SARS-CoV-2 (COVID-19) is the seventh
known coronavirus to infect humans. Like the
SARS-related coronavirus strain implicated
in the 2003 SARS outbreak, COVID-19 is a
member of the subgenus Sarbecovirus. Its
RNA sequence is approximately 30,000 bases
in length. Among the human coronaviruses,
SARS-CoV has exhibited the most genome
similarity to COVID-19 at around 80%. MERS,
on the other hand, shares only about 50%
sequence similarity with COVID-19. Notably,
COVID-19 is nearly identical to a coronavirus
found in bats.
This new strain is novel for its integration of
a polybasic cleavage site, a feature known to
increase pathogenicity and transmissibility.
Electron micrographs of virion particles reveal
a spherical shape with pleomorphism. The
particles have distinctive spikes and give the virions a solar corona appearance. (Figure 3) The
diameter varies from about 60 to 140 nm. Like
other coronaviruses, the spike protein is responsible for allowing the virus to attach to the
membrane of a host cell. Protein modeling experiments focusing on the spike protein reveal
that COVID-19 has an affinity to bind angiotensin-converting enzyme 2 (ACE2) receptors,
which are abundant in the lungs. Studies have
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also shown that COVID-19 has a higher affinity
to human ACE2 receptors than the 2003 SARS
strain. COVID-19 produces at least three virulence factors that promote the dissemination
of new virions from host cells and inhibit the
immune response.8
The nidus of the outbreak appears to have
been the Wuhan seafood market in China. It is
unclear which animal transferred the virus to
humans—bat, snake and pangolin have all been
suggested as potential carriers. The market
in Wuhan is not an unfamiliar environment in
China. Across mainland China, hundreds of
similar markets offer a wide range of exotic
animals for a variety of purposes. The danger of
an outbreak comes when many exotic animals
from different environments are kept closely
together, establishing a setting for cross-species transmission.
As of April 2020, worldwide cases have surpassed 3 million. A large percentage of the
initial cases were residents of Wuhan or those
who had contact with residents of Wuhan. In
China, an estimated 3000 healthcare workers
have been infected.9 The median age of the patients was 47 years, and only 1% of the patients
were younger than 15 years of age.10 There are
nearly 1 million cases in the U.S., with more
than 60,000 deaths reported. This number is
expected to increase in the coming weeks. Italy,
Spain and the United Kingdom have been heavily impacted as well. (Figure 4)

Clinical Signs and Symptoms of
COVID-19

Fever is the most common symptom and is
present on admission in approximately 40%
of patients. However, nearly 90% develop a
fever at some point during hospitalization. The
absence of fever occurs more frequently in
COVID-19 than in SARS-CoV and MERS-CoV.
As a result, afebrile patients may be missed if
screening solely focuses on the detection of
temperature. The second most common symptom is a non-productive dry cough, which occurs in about two-thirds of patients. Less common symptoms include fatigue, sore throat,
nausea, vomiting and diarrhea. Epidemiologic
data from China have shown that approximately one-quarter of patients have at least one
pre-existing medical condition. (Figure 5)

Laboratory and Radiological Findings

On admission, lymphocytopenia is the most
common lab abnormality, occurring in greater
than 80% of patients. Patients with severe
disease tend to have more significant lymphocytopenia and leukopenia than those with milder disease forms. Other lab features include
thrombocytopenia, transaminitis and elevated
inflammatory markers such as C-reactive protein, creatinine kinase and D-dimer.11
Testing for COVID-19 is evolving with time.
The first test to be released, and still the most
widely used, is a nucleic acid amplification
test. More specifically, it is a reverse transcrip-

Figure 4. COVID-19 Pandemic
Credit: European Center of Disease Control
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Fever (87.9%)
Dry cough (67.7%)
Fatigue (38.1%)
Sputum production (33.4%)
Shortness of breath (18.6%)
Myalgia (14.8%)
Sore throat (13.9%)
Headache (13.6%)
Chills (11.4%)
Nausea or vomiting (5%)
Diarrhea (3.7%)

Figure 5. COVID-19 Percentage Frequency of Symptoms
Credit: WHO
tase-polymerase chain reaction (RT-PCR) test,
which tests for the presence of viral RNA. More
recently, an IgM test has been released. However, the CDC warns that antibody testing results
should not be used as the sole test to diagnose,
to rule out or to inform the infection status of
COVID-19. This is mainly because of the potential cross-reactivity of the antibody (poor
specificity) with non- COVID-19 coronavirus
strains (ex. common cold coronaviruses). The
Infectious Diseases Society of America (IDSA)
suggests that these antibody tests would be
better used for public health surveillance and
vaccine development instead. Conversely, for
a patient who is symptomatic, a nucleic acid
amplification test such as RT-PCR will have a
high positive predictive value because of their
high specificity.12
Chest computed tomography (CT) is one of
the primary modalities in the diagnostic algorithm for patients with suspected COVID-19

infection. Given the limited testing capability,
the National Health Commission of the People’s Republic of China has promoted diagnosis
based on clinical and chest CT findings alone.
In a study of over 900 Chinese patients diagnosed with COVID-19, more than 86% of scans
were abnormal. The most common patterns on
chest CT are ground-glass opacities (56%) and
bilateral patchy infiltrates (52%). Radiographic
or CT abnormality was absent in only 3% of
patients with severe disease and approximately
20% of patients with mild forms. (Figure 6)
The pattern of ground-glass and consolidative pulmonary opacities, often with a bilateral
and peripheral lung distribution, seems to be
a radiologic hallmark of COVID-19 infection.
(Figure 7) This pattern of disease is somewhat
similar to that described in earlier coronavirus outbreaks such as SARS and MERS. Other
common radiologic findings with pulmonary
disease such as lymphadenopathy, pleural ef-

Abnormal CT (86%)
Ground Glass opacities (56%)
Bilateral patchy infiltrates (52%)
Normal CT (14%)

Figure 6. CT Scan Findings in Confirmed Cases of COVID-19
Credit: Keswani S. Department of Internal Medicine. MountainView Hospital.
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Figure 7. CT Scans with Typical Findings in COVID-19 Patients
Left: An axial CT image shows ground-glass opacities with a rounded morphology in the right
middle and lower lobes.
Right: An axial CT image shows bilateral ground-glass and consolidative opacities with a peripheral distribution.
Credit: Department of Radiology, Icahn School of Medicine at Mount Sinai, New York. Reproduced with permission.
fusions, pulmonary nodules and lung cavitation
are usually absent.
In a US study of 121 patients with confirmed
COVID-19 infection, after 0-2 days of onset of
symptoms, 56% had a normal CT with a complete absence of ground-glass opacities or consolidation. This was in contrast with less than
10% of patients with normal CT, who presented
later in the disease course.13 Chest CT, therefore, has limited sensitivity and is time-dependent.

Case Fatality

Despite the number of deaths associated with
COVID-19, it appears to have a lower case fatality rate than SARS-CoV and MERS-CoV. Case
fatality varies by age, with older age groups
having higher rates than younger ones, as represented by Figure 8. Most recent estimates by
WHO reports that 3.4% out of all the people
reported infected with COVID-19 have died. We
expect this number to drop as more people are
tested and milder cases surface. Of note, case
fatality can also vary widely by comorbidity and
baseline health status. Critically ill hospitalized
patients with shock, respiratory failure and
multi-organ failure have the highest fatality
rate.

Treatment

Supportive care with supplemental oxygen is

the mainstay of treatment for severe cases. For
hypoxic patients, humidified oxygen via nasal
cannula 1-8 liters per minute (LPM) should be
employed to keep oxygen saturation greater than 92%. If the patient remains hypoxic,
non-humidified oxygen should be administered
via Venturi mask at 9 LPM with FiO2 of 0.28
and up-titration as needed to keep oxygen saturation greater than 92%. If FiO2 requirements
exceed 0.60, intubation with video laryngoscope by the most experienced medical staff
present should be employed.14 If a patient is in
ARDS, the tidal volume should be set to 6 mg/
kg of ideal body weight, with a respiratory rate
of 14-20, and positive end-expiratory pressure
(PEEP) of at least 10 cm H2O. Low PEEP is
not effective in COVID-19 (based on anecdotal
reports from field hospitals in Italy). Sedation
should be implemented if intubated, and prone
positions are likely beneficial based on prior
evidence in patients with ARDS. Inhalers should
be used in lieu of nebulizers to reduce aerosolization of the virus.
No antiviral therapy has been proven to be a
definitive cure or treatment for COVID-19 in
humans. Multiple randomized controlled trials
are ongoing. The vast majority of patients will
do fine without any therapy, so in most cases,
there’s no need for antiviral treatment.
Remdesivir is being investigated in both randomized open-label trials, as well as a dou-
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COVID-19 Case Fatality (Reported Deaths/Reported Cases) by Age Group
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COVID-19 Case Fatality in Percent by Comorbidity
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Figure 8. COVID-19 Case Fatality
Source: CDC (top) and WHO (bottom)

ble-blind, randomized controlled trial involving
up to 50 sites globally.15 Although not commercially available, Remdesivir has been used under
the umbrella of “compassionate use”.
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Lopinavir/ritonavir is a combination pill for
human immunodeficiency syndrome. It is more
widely available than remdesivir and has an
established toxicity profile. Previously, there
has been evidence to show the in-vitro activity
of this drug against SARS CoV.16 However, an
open-label, randomized controlled trial comprising of 199 adults with confirmed COVID-19
infection showed that no benefit was observed
beyond standard care when using lopanavir/
ritonavir.17 Hence its use is not recommended at
this time.

mechanisms, such as interfering with the ACE2
receptor, a potentially important target. They
are also involved with impairment acidification
of endosomes, which can stop intra-cellular
viral trafficking. However, it should be noted
that these drugs have significant adverse effects, including QT prolongation and ventricular
arrhythmias, which may be fatal in critically ill
patients. As more evidence is released, the use
of this medication is becoming controversial.
The first large multicenter randomized controlled trial on hydroxychloroquine consisting of
150 patients that compared it to the standard
of care alone, revealed that there was no difference in the rate of improvement of symptoms
and viral clearance at 28 days.19 This study has
yet to be peer-reviewed.

The now widely popularized non-antiviral
medication hydroxychloroquine is being used in
many facilities. Hydroxychloroquine has shown
in-vitro activity against COVID-19 and has
much broader availability in the United States.18
These antimalarial drugs work via multiple

The role of corticosteroids has also been evaluated. Clinical evidence thus far does not support its use. Data from prior studies on SARS
and MERS show that the clinical outcomes and
complications outweigh any benefit that they
may provide. Corticosteroids reduce inflam-
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mation but also impair the immune response.
When SARS and MERS patients were given
steroids, there was a delayed clearance of viral
RNA. Complications in SARS patients receiving
corticosteroids included psychosis, diabetes
and avascular necrosis.20
Given the known role of type 2 angiotensin-converting enzyme (ACE2) in the pathogenesis of COVID-19, there has been increasing
concern about whether people who are on ACE
inhibitors or angiotensin receptor blockers
(ARB) medications are at increased risk or have
a higher susceptibility to COVID-19 infection.
ACE inhibitors are common anti-hypertensive
agents prescribed widely across all populations.
An ACE inhibitor will inhibit angiotensin-converting enzyme 1 (ACE1), which will upregulate
the angiotensin-converting enzyme 2 (ACE2).
Hence people who are taking ACE inhibitors
will have higher levels of ACE2.
No conclusive data are yet available regarding
a relationship between these agents and poor
outcomes. While ACE2 levels may be increased
in such patients, the evidence is limited for an
increase in pulmonary ACE2 levels. Moreover,
ACE inhibitors have found to be protective in
limited lung injury models in mice. In one such
study, SARS-CoV downregulated ACE2, worsening lung injury, and treatment with ARBs
improved outcomes. Also, patients on these
drugs tend to be older with other comorbidities that may explain their increased mortality.
Professional organizations such as the American College of Cardiology, European Society of
Cardiology, and the American Heart Association have recommended that patients continue
their anti-hypertensive treatment with ACE
inhibitors or ARBs as prescribed.21
Interleukin 6 (IL-6) activates T cells and macrophages, and has been approved in the past for
cytokine activation syndrome and its complications.22 IL-6 levels are possibly correlated with
severe COVID-19 based on bronchoalveolar
lavage of these patients, which show lymphocytosis (despite peripheral leukopenia). IL-6
inhibition, therefore, might be helpful. There
are anecdotal reports of the successful use of
tocilizumab in Italy.
A phase 1 clinical trial for an investigational vaccine has been started by the National Institute

of Health for COVID-19. Current estimates
for approval and availability range from 12-18
months.
Of all the above therapies discussed, at this
point, remdesivir seems to be the most promising for a multitude of reasons. First, remdesivir
has shown good in vitro activity against many
human and zoonotic coronaviruses, including
the SARS-CoV and bat coronaviruses. Therefore it can act as a broad-spectrum antiviral
agent against coronaviruses. Second, remdesivir resistance has been studied, and findings
indicate a high genetic barrier for resistance to
remdesivir to develop. Moreover, remdesivir has
also been studied in murine models with SARSCoV, among others, showing that early therapeutic dosing reduced viral load and improved
pulmonary function. Intravenous remdesivir
therapy was shown to have a compelling safety
profile in two case reports. Two randomized
clinical trials of parenteral remdesivir therapy
for COVID-19 are currently underway in China.
For these reasons, increased use of remdesivir
is highly anticipated.23

Future

We should expect to see an increase in the
number of cases and high death tolls until a
significant amount of the population transitions from susceptible to immune. Healthcare
providers must pay attention to epidemiological terms and methods that will be necessary
to learn and use for this new challenge. The understanding of risk factors, paths of transmission, epidemiological surveillance efforts and
the use of information for intelligent allocation
of resources is necessary.
What practical measures can health care workers employ to protect themselves?
1. Making smart use of personal protective
equipment (PPE), conserve when possible.
2. Practice smart and effective social distancing, even with colleagues, within the healthcare setting.
3. Limit unnecessary length and frequency of
interaction between health care personnel
and patients.
4. Encourage patient face mask usage, especially for confirmed COVID-19 positive
patients.
5. Defer elective or non-urgent care.
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